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Given the complexities of the mammalian CNS, its regeneration is viewed as the holy grail of regenerative
medicine. Extraordinary efforts have been made to understand developmental neurogenesis, with the hopes
of clinically applying this knowledge. CNS regeneration also involves glia, which comprises at least 50% of
the cellular constituency of the brain and is involved in all forms of injury and disease response, recovery,
and regeneration. Recent developmental studies have given us unprecedented insight into the processes
that regulate the generation of CNS glia. Because restorative processes often parallel those found in devel-
opment, we will peer through the lens of developmental gliogenesis to gain a clearer understanding of the
processes that underlie glial regeneration under pathological conditions. Specifically, this review will focus
on key signaling pathways that regulate astrocyte and oligodendrocyte development and describe how these
mechanisms are reutilized in these populations during regeneration and repair after CNS injury.Introduction
A central tenet of regenerative biology is that processes control-
ling tissue generation during development often control its
regeneration: therefore processes regulating developmental
gliogenesis in the CNS are likely to provide critical insights into
glial repair and its influence on homeostasis in the adult CNS.
While injury and pathological states in the adult are compara-
tively more complex than embryonic and early postnatal devel-
opment, viewing regeneration through the lens of development
lends clarity as well as a starting point for greater insight
into the fundamental processes governing glial repair. Therefore,
this review will focus on key glial developmental mechanisms
that are reused during glial regeneration, how these develop-
mental processes are involved in functional recovery of the
CNS, and how they contribute to key neurological disorders.
Recently, microglia have been implicated as also playing key
roles in CNS regeneration, however, because they have different
developmental origins from CNS glia, this review will not cover
microglia. In discussing some of these fundamental mechanisms
and the crucial cellular interactions involved in glial regeneration,
we also hope to demonstrate the potential for future interven-
tions based on identifying putative therapeutic targets. Other
excellent review articles have recently considered these topics
(Burda and Sofroniew, 2014), and we will refer to them in
providing an overview of the field within the limits of the present
article.
The ability of an organism to repair and regenerate its injured
nervous system often correlates with the organism’s longevity
and complexity. For example, flies and worms have short life-
spans and limited capacity to repair their ‘‘CNS,’’ while mice
and humans live comparatively much longer and have remark-
able ability to repair their damaged CNS. The other side of this
equation is that more can go wrong in a CNS with more ‘‘moving
parts’’ (cellular elements and complex interactions). Thus, a level
of quality control must be in place to ensure that homeostasis ismaintained; and the longer you live, the more important this
becomes.
In terms of CNS complexity, what key feature separates inver-
tebrates from vertebrates? Besides the existence of many more
neuronal subtypes in vertebrates versus invertebrates, glia are
clearly a major differentiating element (Freeman and Rowitch,
2013). Invertebrates have a significantly lower proportion of glial
cells, with Caenorhabditis elegans displaying a ratio of 56 glia to
352 neurons (1:6 ratio), while the glia-to-neuron ratio in verte-
brates ranges from 1:1 to 4:1 (depending who you ask). Coupled
with their increasing representation, vertebrates’ glial cells also
show escalating diversity and functional complexity. Particu-
larly, oligodendrocytes (OLs) and myelin sheaths, which are
not present in smaller invertebrates, are necessary and essential
adaptations for rapid nerve conduction in axons of larger verte-
brates. While aspects of astrocyte function are conserved
across species (i.e., glutamate transport), their number and
morphological complexity largely increase from mice to hu-
mans. Indeed, a single hippocampal astrocyte is estimated to
make contacts with 100,000 synapses (Bushong et al.,
2002). This estimate, coupled with recent reports that trans-
planting human astrocytes into the mouse brain enhances
learning and memory, also suggests additional, undiscovered
roles for astrocytes in cognition, further reinforcing their central
and increasingly complex role in CNS physiology in higher
organisms (Han et al., 2013).
This evolutionary evidence, together with the rapid progress
over the last two decades in our understanding of glial biology
and physiology, demonstrates an essential role for glia in CNS
function. Astrocytes and OLs are able to regenerate in response
to CNS injury, and glial regeneration and repair are essential for
long-term homeostasis and for complete recovery of integrated
functions. Given their unique partnerships with neurons and
the extremely limited degree of neurogenesis in the adult CNS,
this capacity also functions to preserve neuronal populationsNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 283
Figure 1. Development of the Astrocyte
Lineage
Schematic synopsis of the cellular and molecular
processes that oversee the specification and
differentiation of the astrocyte lineage. Unlike
neuronal- or oligodendrocyte-lineage develop-
ment, the intermediate stages of astrocyte lineage
development remain poorly defined, due in part, to
the lack of reliable markers and clearly defined
functional endpoints.
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the potential to generate neurons under pathological conditions.
Thus, glial responses to injury and disease serves two main pur-
poses: (1) repair and preservation of existing cell populations,
and (2) regeneration of lost populations, including both neurons
and glia.
Astrocyte Development
Generation of astrocytes involves a complex interplay of intrinsic
and extrinsic cellular signals that act on neural stem cells (NSCs)
and precursor populations to direct their formation. As with the
development of any cell lineage, astrocyte differentiation entails
a sequential series of events that result in the generation of a
mature cell population that actively participates in CNS physi-
ology. Unlike OLs, however, the stages of astrocyte lineage
development are poorly defined, lacking stage-specific markers
and clearly defined developmental endpoints (Molofsky et al.,
2012). Moreover, while astrocytes are a functionally heteroge-
neous population, the cellular nature of their heterogeneity is
just starting to emerge (Chaboub and Deneen, 2012). Many pro-
cesses associated with astrocyte development have long been
shrouded in mystery, but an existing base of knowledge can
be used to frame our discussion on reactive astrocytes. The
following sections briefly review key aspects of astrocyte devel-
opment germane to reactive astrocytes and repair (Figure 1).
Specification and Differentiation
During development, neurogenesis precedes gliogenesis. The
transition is often used as a model for identifying factors that
regulate specification of astrocytes from NSC populations.
This developmental interval—the gliogenic switch—is best char-
acterized in the ventral spinal cord, where several recent studies
found that transcription factors Sox9 and NFIA comprise a tran-
scriptional cascade that regulates glial specification (Deneen284 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.et al., 2006; Kang et al., 2012; Stolt et al.,
2003). Subsequently, Sox9/NFIA asso-
ciate and regulate a set of genes impli-
cated in astrocyte precursor migration
and metabolism, key aspects of lineage
development (Kang et al., 2012). Interest-
ingly, Shh and Notch signaling have been
shown to regulate Sox9 andNFIA, respec-
tively, linking these factors to key develop-
mental pathways active in ventricular
zone (VZ) populations (Namihira et al.,
2009; Scott et al., 2010). Several studies
have implicated both Shh and Notch
signaling in astrocyte development anddifferentiation, although in different regions of the CNS and using
different experimental models (Chambers et al., 2001; Garcia
et al., 2010).
After specification, astrocyte precursors migrate away from
the germinal centers and begin to differentiate. This aspect of as-
troglial lineage development is defined by the induction of glial
fibrillary acidic protein (GFAP), originally identified in reactive as-
trocytes found in demyelinated multiple sclerosis (MS) plaques
(Eng et al., 2000; Gerstl et al., 1970). While GFAP has long
been miscast as the definitive marker of astrocytes, identifying
the processes that regulate its expression gave crucial insight
into the mechanisms regulating astrocyte differentiation. Among
key pathways implicated in GFAP regulation, CNTF/LIF/CT-1
cytokine signaling through gp130 and JAK/STAT has been
shown in several developmental models to be a key regulator
of GFAP and astrocyte differentiation as a whole (Barnabe´-
Heider et al., 2005; Bonni et al., 1997; Miller and Gauthier,
2007; Sun et al., 2001). Additionally, Notch- and BMP-signaling
have been implicated in regulating GFAP-expression and some
aspects of astrocyte development, including inhibition of alter-
native cell fates (Bonaguidi et al., 2005; Grinspan et al., 2000;
Namihira et al., 2009; Taylor et al., 2007). Newborn neurons
are thought to be the source of these signaling molecules,
as separate studies have suggested that CT-1 and Jagged/delta
released from neurons promote astrocyte differentiation in vitro
(Barnabe´-Heider et al., 2005; Namihira et al., 2009). Identifying
the in vivo sources of key astrocyte-promoting signaling mole-
cules during development is important for understanding the
genesis of reactive astrocytes after CNS injury. Given the com-
plex and heterogeneous cellular response to injury, a knowledge
of the normal sources of these key cytokines and signaling mol-
ecules can provide insight into paracrine signaling mechanisms
that operate after injury (Burda and Sofroniew, 2014).
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A distinguishing feature of gliogenesis is the proliferation of pre-
cursor populations outside the germinal centers. Both OL pro-
genitor cells (OPCs) and astrocyte precursors (ASPs) display
robust proliferative potential postspecification (Ge et al., 2012.;
Tien et al., 2012; Fruttiger et al., 1999; Richardson et al., 2011).
In the early postnatal cortex, up to 55% of GFAP+ astrocytes
are generated after migrating away from the germinal centers
(Ge et al., 2012). Similarly, in the developing spinal cord, ASP
populations retain proliferative potential postspecification, sug-
gesting the existence of an ‘‘intermediate astrocyte precursor’’
(IAP) that governs the expansion of astrocyte numbers
throughout lineage development (Tien et al., 2012). The mecha-
nisms governing ASP or IAP proliferation remain poorly defined,
but recent studies implicate BRAF-ERK signaling in the spinal
cord (Tien et al., 2012). Interestingly, separate studies in the cor-
tex indicate that MEK1/2, which also signals through ERK, regu-
lates gliogenesis through the CNTF-STAT3 axis (Li et al., 2012).
Together, these studies suggest a link between the proliferative
and differentiative processes that function in ASPs postspecifi-
cation. Thus, it will be important to identify additional pathways
that couple (or uncouple) ASP proliferation and differentiation
and to determine how the existing programs are reused in reac-
tive astrocyte proliferation.
Emerging Heterogeneity
Astrocytes can be broadly classified into two categories: (1) pro-
toplasmic astrocytes that occupy the gray matter, and (2) fibrous
astrocytes that occupy thewhitematter (WM).However, anabun-
dant cell type capable of a variety of physiological functions is
likely to comprise a vast, reservoir of subtypes and classeswithin
the adult CNS. Indeed, Cajal (1909) described the presence of
several morphologically distinct types of astrocytes in the cere-
bellum.Recent studies have begun the complicated task of delin-
eating astrocytes’ cellular heterogeneity, guidedby the principles
of developmental patterning. A set of recent studies usinggenetic
and lineage-tracing approaches found that molecularly distinct
subtypes of astrocytes originate from separate domains in the
developing spinal cord, indicating embryonic patterning as an
organizing principle in astrocyte, as well as neuronal, diversity
(Hochstim et al., 2008; Tsai et al., 2012). While these patterning
principles have yet to be applied to diverse astrocyte populations
in the adult brain, a recent study usingGFAP- and s100b-reporter
mice identifiedninemorphologicallydistinct classesof astrocytes
distributed in varying constituencies across the adult brain
(Emsley and Macklis, 2006). Given the underlying functional het-
erogeneity of astrocytes and their reactive counterparts, a more
comprehensive understanding of their cellular heterogeneity will
further resolve their roles after CNS injury.
Astrocytes in CNS Injury and Repair
With their key role in subserving normal neuronal function
by operating as a bridge from neurons to the outside world, a
natural extension of astrocyte function after injury would be to
reestablish homeostasis in a pathological microenvironment.
Reactive astrocytes, the astrocytic response to CNS injury,
have been identified in nearly all cases of CNS injury, degenera-
tion, and disease, from multiple sclerosis (MS) and Alzheimer’s
disease, to glioma, spinal cord injury (SCI), and stroke (Sofroniewand Vinters, 2010). Despite their ubiquity in injury and disease,
the properties, functions, and contributions of reactive astro-
cytes to CNS repair remain somewhat mysterious. Below, we
summarize what is known about reactive astrocytes and their
contributions to CNS repair and how recent studies have
changed long-standing views of astrocyte reactivity.
General Properties
Sites of CNS trauma or disease are populated by reactive astro-
cytes with three general properties: (1) expression of GFAP, (2)
cellular hypertrophy, and (3) cellular proliferation. Thus, reactive
astrocytes can be identified by a combination of molecular
markers and cell morphology, coupled with accurate localization
of injury. These properties are graded, with increasing prolifera-
tion and GFAP expression correlated with more severe injury.
Their increased proliferation in severe injury disrupts nonoverlap-
ping ‘‘tiled’’ domains of astrocytes and forms densely packed
areas containing extensive overlapping of astrocytic processes.
Astrocytes play diverse and crucial roles in normal CNS
physiology, regulating synaptogenesis, neurotransmission,
metabolic support, blood-brain-barrier (BBB) formation/mainte-
nance, and other functions not yet characterized (Alvarez et al.,
2013; Halassa and Haydon, 2010; Matyash and Kettenmann,
2010). Unsurprisingly, injury-induced proliferation, hypertrophy,
and tiling disorganization are likely to disrupt these normal func-
tions, and the introduction of new signalingmolecules in an injury
milieu raises the question of whether reactive astrocytes after an
injury are demonstrating a loss of normal functions or the acqui-
sition of new ones (Burda and Sofroniew, 2014). It seems likely
that normal functions such as synaptic transmission, metabolic
support, and BBB formation would aid in repair. Indeed, several
studies have linked these functions to reactive astrocytes and
repair (Faulkner et al., 2004; Rothstein et al., 1996; Swanson
et al., 2004; Voskuhl et al., 2009). But the emergence of new
functions, such as managing the immune response to injury,
also contributes to the repair process (Dong and Benveniste,
2001; Farina et al., 2007; John et al., 2003). While the exact func-
tions of reactive astrocytes after injury remain poorly defined,
one key question remaining is whether distinct types of injury
elicit differential responses from reactive astrocytes and, ulti-
mately, from reactive astrocytes with different repair properties.
Recent studies have revealed that stab wounds and ischemia
give rise to reactive astrocytes with NSC potential, while degen-
erative models do not (Shimada et al., 2012; Sirko et al., 2013).
These observations hint at complex interplays between type of
injury, location, and reactive astrocyte response and function,
which are only now being recognized. Decoding these relation-
ships will be essential to understanding how astrocytes respond
and contribute to CNS repair.
Good Cop? Bad Cop? Both?
Given the inherent complexity of injury states and the hetero-
geneous astrocytic response, perhaps a better question at this
point is: are reactive astrocytes detrimental or beneficial to
CNS repair? The long-standing view of reactive astrocytes is
that they are ‘‘bad actors’’ in the repair process. This view de-
rives from the inhibitory effects of glial scarring on axon regener-
ation after SCI. The glial scar around trauma sites results
from reactive astrocyte proliferation and subsequent accu-
mulation of an astrocytic barrier that physically impedes axonNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 285
Figure 2. Astrocyte Roads to Reactivity
The two key processes associated with astrocyte development that directly contribute to the reactive astrocyte phenotype are proliferation and GFAP-induction.
Molecular regulation of these processes during development is viewed as the road to astrocyte reactivity and understanding how they are recapitulated after
injury will serve as a starting point for understanding the nature of reactive astrocytes.
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(CSPGs), which inhibit axon growth (Busch and Silver, 2007;
Morgenstern et al., 2002). These observations raise a simple
question. If the aftereffects of glial scarring are so bad, why do
scars form in the first place? There is general consensus that
the reactive astrocyte-glial scar axis functions to ‘‘wall off’’ the
damaged area, preventing the spread of inflammatory cells or in-
fectious agents to adjacent healthy tissues, and the axonal inhib-
itory effects are the cost of this benefit (Rolls et al., 2009). Indeed,
ablation or genetic manipulation of reactive astrocytes after SCI
increases local inflammation and neuron loss and generally in-
hibits recovery, indicating that they are essential for repair (Herr-
mann et al., 2008; Sofroniew, 2009).
The view that reactive astrocytes inhibit CNS repair is evolving,
as numerous studies have found that they enhance recovery in a
variety of CNS injury models. While neuronal recovery garners
much of the attention, reactive astrocytes also contribute to re-
covery after white matter injury (WMI), being required for remye-
lination in several lesion models (Franklin et al., 1991; Talbott
et al., 2005). In more complex, inflammatory EAE models of
WMI, the loss of reactive astrocytes increases inflammation
and neuronal loss, although in some cases it also promotes re-
covery (Brambilla et al., 2009; Voskuhl et al., 2009). Thus, in
cases of neuronal or WM repair, despite emerging evidence
that reactive astrocytes facilitate the recovery process, their
deleterious effects may impair long-term recovery for the benefit
of immediate stability. One key area in gaining an understanding
of this duality is the nature of astrocyte heterogeneity. Reactive
astrocytes are clearly not homogeneous, and given that normal
astrocytes play diverse roles in the normal CNS, it is likely that
analogous populations of reactive astrocytes exist after injury
and during repair. Future studies should aim at decoding these
relationships, as more work in this area is clearly needed.
Linking Astrocyte Development to CNS Injury
The developmental processes regulating how astrocytogenesis
contributes to CNS repair remain poorly understood. Unlike the
restoration of OLs and neurons, the restoration of astrocyte pop-286 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.ulations is not a major feature of CNS repair. Thus, the devel-
opmental processes that regulate astrocytogenesis are not
implemented in a manner paralleling development (see Oligo-
dendrocyte Regeneration and Repair in the Adult Brain). It is
possible that astrocytes acquire new properties after injury that
are not necessarily associated with their normal functions, but
are associated with: (1) a new set of regulatory factors, or (2) im-
plementation of the same pathways under vastly different condi-
tions (embryo versus injured adult). Our basic knowledge of
astrocyte development has lagged behind that of OLs and neu-
rons, and this significant gap, combined with the preceding
points, widens the chasmbetween our understandings of normal
and injury-associated astrocytes.
Despite these limitations, fundamental aspects of lineage
development that have beenmolecularly characterized in normal
astrocytes and are associated with reactive and regenerative as-
trocytes may give insight into their injury-associated responses.
These features include GFAP expression and cell proliferation.
While the molecular processes regulating these facets of astro-
cyte development are unlikely to be fully conserved after injury,
these developmental criteria provide an entryway into the nature
of reactive astrocytes after CNS injury (Figure 2).
Regulation of GFAP: Gateway to Reactive Astrocyte
Signaling
For years, GFAP has been used as the definitive marker of
normal astrocyte populations. In some ways, this was necessary
due to a dearth of reliable astrocyte markers, but in other ways it
has hindered the field, as GFAP is not a universal astrocyte
marker and relying on it further clouds an already gray area.
GFAP has received a lot of bad press lately as the field slowly
turns to markers such as Aldh1l1 and Glt1 that are universally
expressed in normal astrocyte populations (for complete list,
see Molofsky et al., 2012).
Despite these limitations, GFAP upregulation remains a cardi-
nal feature of reactive astrocytes, and logic dictates that the
signaling pathways and transcription factors regulating GFAP
expression are likely to be associated with reactive astrocytes.
This area has received intense investigation, implicating several
Neuron
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tors including BMP, LIF/CNTF, and Notch, in the regulation of
astrocyte differentiation and GFAP expression (see above).
Each of these pathways has been linked to reactive astrocytes
and, given their broad reach, it is likely that they contribute to as-
pects of reactive astrocyte physiology and function outside of
GFAP regulation. Therefore, one logical extension is that GFAP
regulation serves as a gateway for identifying factors that influ-
ence reactive astrocytes and their biology. Indeed, several
recent studies on these core GFAP regulatory pathways in reac-
tive astrocytes have revealed a broader scope of functions after
CNS injury, as well as new insights into the biology of reactive
astrocytes.
Notch Signaling. Notch signaling is a central pathway used by
astrocytes during development that regulates both the specifica-
tion of astrocyte precursors from NSCs and their subsequent
maturation. Surprisingly, it has only recently been characterized
in reactive astrocytes. Notch receptors are upregulated in reac-
tive astrocytes after CNS injury, and inhibition of the Jagged 1
ligand suppresses GFAP and endothelin receptor-B (ETB-R)
expression in reactive astrocytes found in focally demyelinated
lesions (Gadea et al., 2008; Morga et al., 2009; Hammond
et al., 2014). Furthermore, g-secretase, a key intracellular regu-
lator of Notch signal transduction, is also upregulated in mouse
models of stroke (Arumugam et al., 2006). Interestingly, anti-
sense inhibition of Notch intracellular domain (NICD) expression
or treatment with g-secretase inhibitors improved functional re-
covery after cerebral artery occlusion (Arumugam et al., 2006).
The improved recovery correlated with increased immune inva-
sion of the peri-infarct region and a decrease in proliferating as-
trocytes. Conditional deletion of Notch1 using GFAP-CreERTM
similarly resulted in increased immune invasion and decreased
astrocyte proliferation, but did not improve recovery, suggesting
that theNotch pathway functions inmultiple cell systems present
in CNS injury (Shimada et al., 2011).
The above studies suggest that suppressing Notch signaling
will decrease the reactive astrocyte ‘‘load’’ and thus improve re-
covery. However, reactive astrocytes also promote CNS recov-
ery, when combined with different injury modalities, in different
brain regions and with different astrocyte constituencies, indi-
cating clearly that the recovery landscape is not a ‘‘unified field.’’
The same principles apply to Notch signaling in reactive astro-
cytes. A recent landmark study using a photothrombic injury
model revealed that Notch signaling is required for subventricu-
lar zone (SVZ)-induced astrocytogenesis postinjury (Benner
et al., 2013). The authors also demonstrated that Notch-regu-
lated, Thbs4-expressing astrocytes comprise a unique subset
of SVZ astrocytes that contribute to microvascular repair. The
role of Notch signaling in reactive astrocytes is only now
emerging; however, it seems likely to be region- and, perhaps
even, injury model-specific. This is underscored by recent
studies in an LPS WMI model, in which reactive astrocytes sup-
press remyelination through ET-1 activation of the Notch ligand
Jagged 1 (Hammond et al., 2014). At the cellular level, this sup-
pression is mediated by Jagged 1 activation of Notch-signaling
in neighboring OPCs, inhibiting their differentiation. These recent
advances in our understanding of Notch signaling in reactive
astrocytes highlight the underlying complexity and suggest anuanced role for this key developmental pathway in reactive
astrocytes during CNS recovery.
STAT3. IL-6, CNTF, and CT-1 cytokines have all been linked
to GFAP expression through activation of STAT3 in astrocytes
(Miller and Gauthier, 2007). Because the discovery that activated
STAT3 is a key transcriptional regulator of GFAP expression,
STAT3 expression has been chronicled in reactive astrocytes
in various injury models across several CNS regions, becoming
a hallmark of reactive astrocytes (Choi et al., 2003; Justicia
et al., 2000; Xia et al., 2002). Its role in reactive astrocytes is
best characterized in glial scarring after SCI, where conditional
deletion of STAT3 in NSCs or astrocytes significantly impairs
functional recovery (Herrmann et al., 2008; Okada et al., 2006).
In both these studies, glial scar formation was compromised
by decreased proliferation and migration of STAT3/ astro-
cytes, resulting in greater inflammation and lesion volume.
Mechanistic studies suggest that STAT3 mediates scar forma-
tion and recovery by regulating responses to oxidative stress
and sequestration of inflammatory cells (Sarafian et al., 2010).
Generation of reactive astrocytes after injury occurs in a
cellular milieu comprising several cell types, including immune
cells and OLs. Given that reactive astrocytes are generated in
a complex pathological cellular environment, it is no surprise
that the cytokines regulating STAT3 expression are also found
in inflammatory cells in several injury models (Choi et al., 2003;
Okada et al., 2004; Sriram et al., 2004). Equally interesting is
the cellular interplay of OLs, microglia, and reactive astrocytes
orchestrated by STAT3. In a recent study, deletion of STAT3 in
astrocytes suppressed remyelination after WMI. Mechanisti-
cally, STAT3/ astrocytes promoted TGFb-1 expression in
microglia, which subsequently suppressed OPC differentiation
after injury (Nobuta et al., 2012). This study highlights not only
new roles for STAT3 in reactive astrocytes, but also the complex-
ities of paracrine signaling between cellular compartments
present in injury. Undoubtedly, future studies will investigate
whether similar paracrine mechanisms underlie STAT3 func-
tion in reactive astrocytes in other CNS injury and regenera-
tion models, as injury conditions or location may dictate the
STAT3-response in reactive astrocytes themselves.
BMP Signaling. The convergence of cellular constituency
and signaling complexity after CNS injury—and its influence on
regeneration and repair processes—are perhaps best illustrated
by the BMP pathway. BMP signaling plays a key role in astrocyte
differentiation and is also activated in reactive astrocytes after
various CNS injuries, including SCI, ischemia, hypoxia, and
WMI (Lewe´n et al., 1997; Martinez et al., 2001; See and
Grinspan, 2009; Setoguchi et al., 2001). Several groups have
manipulated BMP signaling in a variety of injury models by
administering noggin or BMP ligands, each having a different ef-
fect on repair. For example, adding BMP ligand after ischemic
injury promoted functional recovery, while several studies indi-
cate that BMP secreted from reactive astrocytes suppresses re-
myelination in WMI models (Chang et al., 2003; Martinez et al.,
2001; Sabo et al., 2011; Wang et al., 2011). The latter findings
are supported by several developmental studies, indicating
that BMP signaling suppresses normal OPC differentiation
(Gomes et al., 2003; See et al., 2004). Thus, BMP signaling in
reactive astrocytes during injury response is both detrimentalNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 287
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population being repaired. This duality is best shown in SCI
models, where conditional deletions of BMPR1a or BMPR1b in
astrocytes have opposing effects on glial scar formation (Sahni
et al., 2010). BMPR1a-cKO demonstrate reduced gliosis,
increased lesion volume, and impaired motor recovery, while
the BMPR1b-cKO display increased GFAP expression and
decreased lesion volume in acute injury, accompanied by
reduced scarring in chronic states. The vastly different effects
of these receptor subunits on reactive astrocytes in SCI add
another layer of regulatory complexity to BMP signaling in CNS
injury. Such complexities are likely to be present in other
signaling systems that operate in reactive astrocytes or other
cell types associated with injury, but have yet to be discovered.
Astrocyte Proliferation: A Path to Regeneration?
The mechanisms regulating astrocyte proliferation during devel-
opment are poorly understood, partly because a clearly defined
postmitotic stage has not been identified during astrocyte matu-
ration. However, the presence of GFAP-expressing astrocytes
with proliferative potential in the postnatal cortex parallels the
transient amplifying ‘‘astrocyte’’ population in the stem cell niche
of the SVZ, allowing us to infer that normal astrocytes harbor
latent NSC potential associated with their proliferative response
to injury (Kriegstein and Alvarez-Buylla, 2009). Reactive astro-
cytes demonstrate enhanced production of multipotent NSCs
in vitro, suggesting that under proper conditions proliferating
reactive astrocytes can acquire NSC-like properties (Robel
et al., 2011) and raising the question of whether the mechanisms
controlling postinjury astrocyte proliferation similarly regulate
dedifferentiation to NSCs and possible neuronal regeneration.
Several recent studies are unraveling the processes regulating
astrocyte proliferation and their role, if any, in the astrocyte-
NSC axis.
BRAF/Mek/ERK Signaling Axis.Recently, Mek and BRAF have
been implicated in astrocytogenesis and precursor proliferation
during development, respectively (Li et al., 2012; Tien et al.,
2012). Given that both Mek and BRAF function through the
MAPK-ERK signaling axis, these findings implicate a central
signaling pathway in astrocyte generation. While specific
expression of activated Mek and BRAF in reactive astrocytes re-
mains limited, activated ERK and MAPK have been detected in
reactive astrocytes in various injury models (Carbonell and Man-
dell, 2003; Mandell et al., 2001; Mandell and VandenBerg, 1999).
In ischemia, pharmacological manipulation of p38 MAPK or ERK
promotes recovery, although its effect on reactive astrocyte pro-
liferation was never examined (Gadea et al., 2008; Namura et al.,
2001). In WMI injury models, activated ERK is present in reactive
astrocytes andmediates ET-1-dependent astrocyte proliferation
in lesions (Gadea et al., 2008). ERK has also been implicated
recently in S1P signaling in reactive astrocytes associated with
human MS (Fischer et al., 2011). However, the precise cellular
site of action and its influence on the role of MAP-ERK signaling
repair remain poorly defined.
More broadly, delineating the upstream and downstream
biology surrounding possible BRAF-Mek-ERK signaling in reac-
tive astrocytes is extremely complex. This pathway mediates a
myriad of cellular responses in various forms of CNS injury. How-
ever, in the context of the astrocyte-NSC axis, EGF signaling288 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.plays a major role in NSC formation and functions through the
MEK-ERK pathway, which is also implicated in NSC formation
(Burrows et al., 1997). This fact, coupled with observed expres-
sion of EGFR in reactive astrocytes and EGF in sites of injury,
leads to speculation that EGF signaling through the BRAF-
Mek-ERK axis in proliferating reactive astrocytes provokes
conversion to a NSC-like identity, ultimately stimulating neuro-
genesis (Planas et al., 1998). Such endogenous repair mecha-
nisms are intriguing and somewhat advantageous, but newborn
neurons derived from reactive astrocytes after injury have not
been documented in vivo, and cortical transplantation of NSCs
derived from reactive astrocytes from ischemia models did not
support neurogenesis (Shimada et al., 2012).
Sonic Hedgehog Signaling. The role of Shh in normal astro-
cytes is complex, as it is required for patterning and therefore
indirectly contributes to generating patterned astrocyte subpop-
ulations (Ericson et al., 1997; Hochstim et al., 2008). Consistent
with a role in astrocyte development, deletion of smoothened
(Smo) results in gliosis in subsets of astrocytes in the cortex
and spinal cord, suggesting that Shh signaling suppresses their
proliferation and implying stage-specific roles for Shh in astro-
cyte patterning and differentiation (Garcia et al., 2010; Yu
et al., 2013). However, in a stab-wound/freeze CNS injury model,
Shh is expressed in reactive astrocytes and pharmacological in-
hibition via cyclopamine impairs their proliferation (Amankulor
et al., 2009). Further evidence of a role for Shh is the expression
of the Shh target, Olig2, in reactive astrocytes associated with
varied CNS injuries. Analogous to Shh inhibition, conditional
deletion of Olig2 in astrocytes results in decreased reactive
astrocyte proliferation after injury (Chen et al., 2008). Thus, the
role of Shh appears to vary significantly between normal and
reactive astrocytes and points again to the differing cellular
milieus in development and in injury.
Given the link between astrocyte proliferation and NSC-like
states and the effect of Shh as a potent inducer of NSCs and
reactive astrocyte proliferation, it seems natural that Shh may
regulate aspects of the astrocyte-NSC axis associated with
injury. Indeed, these observations were beautifully integrated in
a recent study characterizing Shh responses in reactive astro-
cytes across a spectrum of CNS injury models (Sirko et al.,
2013). Sirko et al. (2013) demonstrate that reactive astrocytes
acquire NSC-like properties in stab-wound, but not degenerative
CNS injury. Shh expression correlates with reactive astrocytes
having NSC-like properties, and conditional knockout of Smo
in reactive astrocytes decreases their proliferative response
and NSC-forming capacity. These observations reinforce the
broader point that not all reactive astrocytes are ‘‘created equal’’
and this heterogeneity may be induced by injury states. Alterna-
tively, the role of Shh signaling in patterning and astrocyte diver-
sity may also indicate that subsets of astrocytes are differentially
responsive to signaling and act accordingly. Indeed, recent
studies in human ESCs found that astrocytes derived from
Olig2-expressing neural progenitor cells promote recovery after
ischemia, suggesting that Shh signaling may be differentially
used in reactive astrocyte populations after injury (Jiang et al.,
2013).
While provocative and promising, these findings must be
interpreted with tempered optimism, as characterizing the NSC
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In vitro culture is well known to change the properties of CNS-
derived cells, and the Shh-Olig2 axis is especially prone to
such deregulation in NSC culture (Gabay et al., 2003). Definitive
proof that reactive astrocytes acquire NSC-like properties with
neurogenic potential will require complementary conditional
lineage tracing analysis, to distinguish the ‘‘actual’’ from the
‘‘possible’’ (Anderson, 2001).
Oligodendrocyte Development
Our knowledge of OL development derives from an extensive
range of genetic and biochemical tools—particularly cellular
markers and cell-specific gene promoters—that have enabled
detailed characterization of OPCs and lineages able to generate
OLs during embryonic and postnatal development (Emery,
2010a; Kessaris et al., 2006; Richardson et al., 2006). These tools
have also been used to analyze OL turnover and regeneration in
adult brain (Fancy et al., 2011a; Franklin and Ffrench-Constant,
2008; McTigue and Tripathi, 2008; Miller and Mi, 2007). The op-
portunity to identify and fate-map developing OLs in diverse
brain regions has revealed cellular factors and intrinsic molecular
pathways functionally involved in OL development and regener-
ation. This analysis has also illuminated and defined cellular in-
teractions between OLs and other neural cells with critical roles
in development and pathology. Damaged OLs can be replaced
by new cells derived from OPCs that proliferate and differentiate
after injury or in disease. Thus, studies elucidating altered
development in a perturbed cellular environment will reveal
how interactions between intrinsic OPC properties and the injury
milieu determine the cells’ fate. As many excellent articles have
recently reviewed OL development in embryonic and postnatal
brain (Emery, 2010b; Liu and Casaccia, 2010; Meijer et al.,
2012; Miller, 2002; Mitew et al., 2013; Nishiyama et al., 2009;
Richardson et al., 2006), we will focus on some salient aspects
of this topic.
Embryonic Development
In the embryo, OLs originate from multiple progenitor cell pools,
which populate distinct regions of the developing spinal cord
and brain and mature during different time periods. Although a
specialized OL domain (pMN domain) was originally thought to
exist in the ventral ventricular zone (VZ) of the spinal cord and
perhaps in the forebrain (for review, see Rowitch, 2004), recent
investigation has demonstrated dorsal—as well as ventral—ori-
gins of OLs in both spinal cord and brain (for review, see Richard-
son et al., 2006). This conclusion is based on analysis of Nkx6.1
and Nkx6.2 double mutant mice, in which pMN-derived OPCs
are absent from the spinal cord due to impaired Olig2 activation
by Nkx6. In these mice, OPCs that express all the proper
markers—including the paired box gene Pax7—are still pro-
duced in the dorsal spinal cord (Cai et al., 2005; Vallstedt et al.,
2005). Further Cre-lox fate-mapping analysis using Dbx1 or
Msx gene promoter elements to control Cre recombinase
expression showed that dorsally derived OPCs arise from
different domains and generate 10%–50% of dorsal OLs, de-
pending on their origin (Fogarty et al., 2005). Dorsal OPCs are
also generated later in development than pMN-derived OPCs
(Cai et al., 2005; Fogarty et al., 2005; Vallstedt et al., 2005).
Shh signaling activates Olig2 in the pMN domain (Lu et al.,2002), whereas dorsally derived BMPs and Wnts support
generation of astrocytes and prevent OL development at earlier
embryonic stages (Mekki-Dauriac et al., 2002; Shimizu et al.,
2005; Vallstedt et al., 2005). It has also been suggested that
FGF signaling is required to specify OLs in the dorsal spinal
cord (Vallstedt et al., 2005). In any case, distinct and restricted
OPC domains exist in developing spinal cord and are respon-
sible for multiple waves of OPC production influenced by
different cellular factors.
In the forebrain, fate-mapping analysis also demonstrated
distinct temporal waves of OPC production from separate
domains (Kessaris et al., 2006). The main separate domains
identified were the medial ganglionic eminence (Nkx2.1-derived
ventral precursors fromE12.5), the lateral ganglionic eminence
(Gsh2-derived; a few days later), and the cortex Emx1-derived
precursors that produce OPCs predominantly after birth. All pre-
cursors migrate vigorously from the VZ to populate distant brain
regions, and the population of most ventrally derived precursors
disappears after birth (Kessaris et al., 2006).
Postnatal Development
In the postnatal brain, the SVZ is the major source of OPCs and
OLs (Aguirre et al., 2007;Menn et al., 2006; Nait Oumesmar et al.,
1999). Located around the tips of the lateral ventricles, this re-
gion is mostly derived from the embryonic lateral ganglionic
eminence and lateral cortex. Pioneering work using retroviral la-
beling of dividing cells in the SVZ showed that cells in this brain
region are able to generate both OLs and astrocytes (Levison
and Goldman, 1993), and more recent analysis of postnatal
and adult brains demonstrated that proliferative OPCs in the
SVZ express NG2 and Olig2, as well as other OPC and progen-
itor markers including PDGFPa and Mash1 (Aguirre et al., 2004,
2007; Menn et al., 2006). In the adult SVZ, OPCs express a type
C cell phenotype and derive from type B stem cells (Aguirre et al.,
2004). During postnatal development, OPCs migrate from the
SVZ into WM regions, where they stop dividing and differentiate
into mature myelinating OLs (Aguirre et al., 2007; Gonzalez-
Perez et al., 2009; Levison and Goldman, 1993; Menn et al.,
2006). The accessibility of the postnatal SVZ and its ease of
manipulation have facilitated the analysis and identification of
cellular factors and molecular pathways regulating OPC prolifer-
ation, migration, and differentiation. This highly gliogenic region
of the postnatal/adult brain has been intensively studied in ani-
malmodels of injury and pathology to define pathways that could
be used for OL regeneration.
Oligodendrocyte Regeneration in the Developing Brain
Animal Models of Developmental Injury and Pathology
This section will focus on examples of pathological insults in the
immature brain to illustrate the differential responses of distinct
OPC populations and to relate these responses to regeneration
and repair. We limit our discussion to models of injury and pa-
thology that have contributed to defining cellular and molecular
pathways involved in OL andmyelin regeneration and repair dur-
ing development. OPCs’ ability to react to injury may be greater
in the young adult brain (Ruckh et al., 2012), and these early
mechanisms are potentially applicable to the less favorable envi-
ronment of the pathological adult brain (van Wijngaarden and
Franklin, 2013). Furthermore, interventions targeting specificNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 289
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ful during a period of ongoing developmental programs that
would permit a higher degree of neural plasticity. Identification
of signaling systems activated after brain injury or during the
course of neurological disorders can guide strategies that lead
to more robust amplification of the OPC pool and to enhanced
repopulation, regeneration, and functional recovery of the injured
brain.
Perinatal Hypoxia and Ischemia
Animal models of neurodevelopmental disorders and neonatal
brain injury attempt to reproduce different aspects of the pathol-
ogies found in humans. However, these animal models should
satisfy the following criteria: (1) themodel must accurately reflect
the histopathological spectrum of a specific injury to the
developing brain, (2) the model should display a phenotype
that correlates with developmental changes observed in hu-
mans, and (3) the model should display abnormal functional out-
comes also observed in human pathology.
Cerebral WMI and brain gray matter atrophy are the most
frequent brain insults in preterm infants and major causes of
disability in survivors.WMabnormalities in preterm infants persist
throughout adolescence and young adulthood (Hack et al., 2002).
Chronic periventricular white matter injuries (PWMIs) comprise a
broad spectrum, including the most severe form—focal cystic
necrotic lesions (periventricular leukomalacia [PVL])—or diffuse
hypomyelination (diffuse white matter injury [DWMI]). PWMI is
directly associated with adverse outcomes such as cerebral
palsy, cognitive delay, and learning disabilities (Hack et al.,
2002). Although other animal models have been extensively uti-
lized (Back and Rosenberg, 2014; Salmaso et al., 2014), the two
primary animalmodels of prematurebrain injury represent hypox-
ia/ischemia (HI) (Rice et al., 1981) and chronic perinatal hypoxia
(HX) (for review, see Back and Rosenberg, 2014; Scafidi et al.,
2009; Vaccarino and Ment, 2004). Both models result in neuro-
pathological changes resembling those seen in premature human
infants, including severe hypomyelination and decreased gray
matter volume (Salmaso et al., 2014).
Glial cell types susceptible to insult in chronic PWMI have
been identified by their expression of cell-specific markers.
OLs are particularly vulnerable to PWMI, but microglial activation
and astrogliosis are also observed, along with axonal injury. In
chronic PWMI, the maturation of late OPCs/pre-OLs is believed
to arrest at a premyelinating stage, contributing to myelination
failure in PWMI (Back et al., 2002). Indeed, maximal PWMI sus-
ceptibility in preterm infants and perinatal rodents corresponds
to developmental stages characterized by a sizable and suscep-
tible population of late OPCs (Back, 2006). In perinatal HX, anal-
ysis of different cell populations in the OL lineage also indicated
occurrence of delayed OLmaturation, along with specific abnor-
malities in myelin ultrastructure, even when overall myelination
levels appeared normal (Jablonska et al., 2012; Scafidi et al.,
2014). Consistent with this finding, WM changes showed recov-
ery in some prematurely born adolescents or young adults, but
physiological and behavioral abnormalities of WM function still
occurred (Nagy et al., 2003; Fjell et al., 2011). Thus, early inter-
vention is critical for OL regeneration after PWMI and requires
identification of unique specific cell populations in the brains of
premature infants to promote WM recovery after neonatal injury.290 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.Sources of OPCs
Paralleling the effects on OPC differentiation and delayed OL
maturation described above, HI- or HX-induced WMI also pro-
duced regenerative responses. Several studies demonstrated
enhanced SVZ progenitor cell proliferation and migration after
insult to the perinatal brain—an event resulting in significant
expansion of neuronal and glial progenitor pools. Increased
SVZ cell proliferation was observed within 2 days after HI and
within 6 days of chronic perinatal HX and persisted for several
weeks (Fagel et al., 2006; Felling et al., 2006). HX-induced prolif-
eration of NG2-/Olig2-expressing OPCs occurs in the SVZ within
the first few days after insult and depends on activation of the
Cdk4 pathway (Jablonska et al., 2012). Hypoxic rearing doubled
the number of Blbp+Glast+GFAP+ cells in mouse SVZ during the
first week of recovery (Fagel et al., 2006), and a similar prolifera-
tive response occurred after perinatal HI (Ong et al., 2005; Plane
et al., 2004). After HI, SVZ precursor cells display multipotency
in vitro and generate more neurons and OLs in vivo (Yang and
Levison, 2006; Zaidi et al., 2004). These cellular dynamics sug-
gest that the early postnatal SVZ is a potential source of OPCs
as well as other progenitor cell populations for repair. Studies
of the SVZ have shown that OPC proliferation is key to repair
and that identifying regions with this potential is essential for
targeting specific progenitor cell populations and signaling path-
ways involved in OL regeneration.
Another major source of OPCs is the parenchyma, including
the WM itself. OPCs in the parenchyma express the same
cellular markers (NG2, PDGFRa, Olig2) as their SVZ counterpart
(Aguirre et al., 2007; Jablonska et al., 2012; Scafidi et al., 2014).
Fate-mapping analysis showed PDGFRa-expressing OPCs to
be a major source of newly generated OLs in the WM following
HX (Scafidi et al., 2014).
OPC Proliferation Drives Oligodendrocyte Regeneration
The studies discussed above indicate that proliferation of imma-
tureprogenitor cell populations is necessary for glial regeneration.
Therefore, we will briefly describe some molecular mechanisms
that regulate OPC proliferation after neonatal brain injury.
Significant OL death in the brain occurs within the first 2 weeks
after perinatal HX, resulting in transient hypomyelination (Jablon-
ska et al., 2012). OPCs in the parenchyma—particularly
in subcortical WM—actively divide and regenerate OLs after
HX (Jablonska et al., 2012; Scafidi et al., 2014). Immuno-
cytochemical and fate-mapping analysis demonstrated that
NG2+PDGFRa+ OPCs proliferate within a week after HX and
generate new OLs for the following 3–4 weeks (Jablonska et al.,
2012; Scafidi et al., 2014). Unlike the SVZ, OPC proliferation in
WM depends on Cdk2 activation and formation of the Cdk2/
CyclinE complex, a major regulator of G1-S transition in the
OPC cell cycle in both developing and adult brains (Jablonska
et al., 2012; Belachew et al., 2002). The proliferative response
of endogenous OPCs to HX is crucial for expanding this progen-
itor pool and for regenerating a normal number of OLs, restoring
normal myelin protein levels (Jablonska et al., 2012; Scafidi et al.,
2014). Conversely, blockage of signaling pathways (e.g., EGF/
EGF-receptors) that promote OPC expansion after HX impairs
OL regeneration and functional recovery (Scafidi et al., 2014).
What molecular mechanisms delay or prevent timely OL
maturation from OPCs after HX? Do these mechanisms involve
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normal physiological conditions? At least two pathways of func-
tional importance in OL development play essential roles in OL
regeneration: p27Kip1 and Wnt signaling. Importantly, alterations
in molecular elements of these pathways have been noted in an-
imal models of premature brain injury, as well as in postmortem
brain tissue of infants who died of hypoxic/ischemic encepha-
lopathy (Jablonska et al., 2012; Scafidi et al., 2014).
Many studies have contributed to identifying p27Kip1 as an
important regulator of OL differentiation (Casaccia-Bonnefil
et al., 1997): p27Kip1 knockout mice display fewer OLs, and sig-
nals that prevent OL maturation also increase p27Kip1 levels
in OPCs (Casaccia-Bonnefil et al., 1997; Ghiani et al., 1999).
p27Kip1 levels are significantly reduced in the OL lineage of
mice exposed to HX and in human postmortem tissue, and the
effects of HX on OL development are enhanced in p27Kip1 null
mice (Jablonska et al., 2012). HX regulates p27Kip1 via at least
two mechanisms: (1) by reducing expression of FoxO transcrip-
tion factors, which are required tomaintain normal p27Kip1 levels,
and (2) by enhancing activity of the p27Kip1-degrading enzyme
Skp2, which causes ubiquitination of the cyclin kinase inhibitor
(Jablonska et al., 2012).
Wnt-b-catenin plays an important role in OL development, as
downregulation of this signaling pathway is required for OL
maturation (Fancy et al., 2009). Transcription factors (e.g.,
Sox17) and cellular signals that promote OPC differentiation
and myelination suppress Wnt-b-catenin signaling (Chew
et al., 2011). Axin2, one of the negative regulators of Wnt-b-cat-
enin, is expressed at higher levels in OPCs than in OLs and
induces b-catenin degradation (Fancy et al., 2011a). HX destabi-
lizes Axin2, but treatment with a small molecule inhibitor of the
enzyme tankyrase prevents this effect and promotes new OL
generation and timely myelination (Fancy et al., 2011a). The find-
ings discussed above on p27Kip1 and on Wnt-b-catenin not only
demonstrate clear links between OL development and regener-
ation/repair, but also show that manipulation of molecular
pathways regulating OL maturation under normal physiological
conditions may hold important therapeutic implications for pro-
moting regeneration of these cells and preventing hypomyelina-
tion after neonatal brain injury.
Growth and Trophic Factors: Therapeutic Insights
A multitude of growth and trophic factors regulate OL develop-
ment, especially OPC proliferation, migration, and differentiation
(Bansal, 2002; Baron et al., 2005; Miller, 2002). Similarly, OL
survival and myelin maintenance depend on growth and trophic
factors (Casaccia-Bonnefil, 2000; Nave and Trapp, 2008). An
important question, which may have significant therapeutic im-
plications, is whether these factors’ availability is altered in the
pathological immature brain after neonatal injury. If changes
in the overall levels of specific growth factors induced by injury
mimic those seen during normal development that would
indicate reactivation of endogenous developmental programs
aimed at OL recovery. Several studies have harnessed our
developmental knowledge of these factors for therapeutic inter-
ventions aimed at OL regeneration.
Fibroblast growth factor 2 (FGF2), epidermal growth factor
(EGF), and leukemia inhibitory factor (LIF) are upregulated in
the SVZ after hypoxic insult (Covey and Levison, 2007; Ganatet al., 2002; Scafidi et al., 2014). These factors promote OL
generation from OPCs, as well as OL maturation and survival
during normal development. Experimental analysis indicates
that these factors cause: (1) expansion of the SVZ progenitor
pools observed after HX, and (2) generation of new OLs from
these progenitors (Covey and Levison, 2007; Ganat et al.,
2002; Scafidi et al., 2014). Similarly, insulin-like growth factor-
1 (IGF-1) plays a crucial role in promoting oligodendrogenesis
and myelination in early brain development (Carson et al.,
1993; Ye et al., 2002). IGF-1 treatment after neonatal brain
injury recapitulates some developmental effects of this growth
factor and promotes OL regeneration. IGF-1 administration pre-
vented immature OL death, enhanced myelination after HI and
protected OPCs in the SVZ and WM regions (Lin et al., 2005;
Zhong et al., 2009).
We recently observed upregulation of endogenous EGF inWM
and the SVZ after perinatal HX and showed that EGFR overex-
pression in the OL lineage enhances OL regeneration and pro-
motes functional recovery inWM (Scafidi et al., 2014). Consistent
with these findings and with EGF’s effects on OL during normal
development, noninvasive intranasal EGF delivery during a crit-
ical developmental time window immediately after HX causes
significant expansion of the OPC pool in WM and promotes OL
regeneration and functional/behavioral recovery (Scafidi et al.,
2014). Although EGF appears to act via various mechanisms, a
major effect is to prevent HX-induced Notch activation in OL line-
age cells, inhibiting OPC differentiation and contributing to the
delay in OL maturation observed after HX (Scafidi et al., 2014).
This EGF-Notch interaction occurs in the SVZ during normal
development and regulates the size of the OPC pool in this
neurogenic region (Scafidi et al., 2014). To summarize, EGF pre-
vents the delay in OL maturation caused by HX by generating a
significant number of new OLs and inhibiting signaling pathways
that arrest OPC maturation.
A similar therapeutic intervention developed in an animal
model of intraventricular hemorrhage (IVH)mimics amajor cause
of WMI in preterm infants. The intervention was based on the
well-established idea that thyroid hormone (TH) signaling—
involving TH receptor a (TRa) and TRb—strongly promotes OL
maturation and myelination. It was hypothesized that IVH would
decrease TH levels and reduce TH signaling. Interestingly, in
both preterm brain tissue and rabbits with IVH, levels of TH-acti-
vating enzyme deiodinase-2 were reduced, whereas TH-deacti-
vating enzyme deiodinase-3 increased (Vose et al., 2013).
Treating IVH pups with TH accelerated OPC proliferation and
maturation into OLs, enhanced myelination, and restored neuro-
logical function (Vose et al., 2013).
Together, the EGF and the TH treatment paradigms demon-
strate that targeting specific factors required during normal
development for OPC proliferation, survival, and differentiation
might represent a viable therapeutic strategy in pathologies
associated with premature brain injury. The studies also uncover
the existence of rather specific time windows of intervention that
closely follow the injury and likely permit enhancing plasticity
processes to occur in the developing WM. Importantly, a study
in human neonatal tissue demonstrated that neurogenesis
ceases after 18 months, but OPCs are detected in the SVZ after
this age (Sanai et al., 2011), strongly indicating that gliogenesisNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 291
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developmental stages of the postnatal brain.
A different approach was undertaken in rodent models of HI
to target iron, an essential trophic factor for OL development
and survival. Iron plays a crucial role in oxygen consumption
and ATP production in all cells, but OLs are the major brain cells
that stain for iron, indicating higher levels (Todorich et al., 2009).
Iron deficiency causes hypomyelination and neurological abnor-
malities, which can be reversed by intracranial injection of apo-
transferrin (aTf) at early developmental stages (Badaracco
et al., 2008). The use of aTf to restore physiological levels of
iron transport has been explored in neonatal WMI after HI, as
HI increases iron release in WM regions (Guardia Clausi et al.,
2012). Intranasal administration of aTf immediately after HI pro-
moted neuroprotection of the neonatal mouse brain by reducing
WM damage, astrogliosis, and OL death. The treatment also
enhanced OPC proliferation in the SVZ and corpus callosum
and promoted OPC differentiation. Overall, this noninvasive
treatment acting on a signal with a crucial role in normal develop-
ment also promoted functional recovery. The results obtained
with aTf also suggest that future studies could investigate the
use of combined treatments (e.g., EGF+aTf) delivered at different
times after neonatal injury.
Transcription Factors and Epigenetic Regulation
Despite extensive characterization of transcriptional regulation
of OPC development/differentiation, the reuse of these pro-
cesses after neonatal HX or HI remains poorly defined. Myt1
and NFIA, two transcription factors with important roles in
OL development, were recently studied in animal models of
neonatal HX and in PVL tissue. Myelin transcription factor 1
(Myt1) is a zinc finger DNA-binding protein expressed at higher
levels in OPCs than in mature OLs (Armstrong et al., 1995).
Based on its expression pattern, regulation, and functional anal-
ysis, Myt1 is thought to modulate OPC transition from a prolifer-
ative to a terminally differentiated state that requires high levels
of myelin gene transcription (Armstrong et al., 1995; Nielsen
et al., 2004). Interestingly, in normally developing human brains,
many Myt1-expressing glial cells are found between gestational
weeks 19 and 26 but decrease by 1 year of age (Hirayama et al.,
2003). In PVL brains, a large increase in Myt1-expressing cells is
observed around necrotic foci and in regions displaying higher
levels of myelin protein immunoreactivity (Hirayama et al.,
2003), strongly suggesting their role in human OL pathology/
regeneration.
A similar pattern of developmental regulation was observed for
NFIA in OLs. During mouse embryonic development, NFIA is ex-
pressed in OPCs but not in differentiated OLs; its overexpression
prevents OPC differentiation by directly repressing myelin gene
expression (Fancy et al., 2012). Notably, in HIE lesions, NFIA is
expressed in OPCs, but not in PLP-expressing cells (Fancy
et al., 2012), indicating that NFIA dysregulation may contribute
to the delayed OPC maturation and hypomyelination found in
HIE, by repressing myelin gene expression. Indeed, misexpres-
sion of NFIA suppressed remyelination in an adult LPS model,
suggesting a conserved function after WMI.
Epigenetic mechanisms, including DNA and histone methyl-
ation and acetylation, represent a different level of develop-
mental regulation of the OPC-OL transition. In normal brain,292 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.timely OPC differentiation and myelination require histone de-
acetylation (HDAC) during a critical developmental time window
(Shen et al., 2005), and HDAC activity regulates the regenerative
potential of OPCs during development (Shen et al., 2008). Some
hypothesize that epigenetic mechanisms—including acetyla-
tion/deacetylation and methylation—are involved in neurode-
generative diseases and stroke as regulators of the extent of
injury (Lo´pez-Otı´n et al., 2013; Schweizer et al., 2013). Altered
gene expression caused by ischemia is an important contributor
to neuronal or glial damage, and HDAC inhibitors have attracted
significant attention as potential neuroprotective agents (Kumral
et al., 2009, 2013). Although the role of HDAC and HDAC inhib-
itors has been specifically investigated only in regeneration
and remyelination of adult OLs (see below), particular alterations
in HIF-mediated gene transcription have been observed in
neonatal HI (Kumral et al., 2009; Singh et al., 2012). Thus, it will
be important to define changes in DNA methylation and acetyla-
tion following HX or HI, as these changes will strongly influence
the expression of genes involved in OL regeneration andWM re-
covery in the neonatal brain. Finally, as significant sex differ-
ences have been observed in the extent of premature brain
injury—males being more susceptible than females—sex differ-
ences in histonemodifications (Tsai et al., 2009)might account at
least partially for differential vulnerability seen inWM of male and
female infants.
Future studies will further investigate the links between spe-
cific growth factor signaling pathways and differing levels of tran-
scriptional regulators after developmental injury and during
regeneration. Understanding these signaling axes will be crucial
to generating new therapeutic approaches based on molecular
mechanisms regulating normal glial development.
Oligodendrocyte Regeneration and Repair in the Adult
Brain
The hope for OL replacement in various myelin disorders and
in adult WMI rests on the established finding that the adult
brain contains populations of undifferentiated OPCs able to
divide and regenerate myelinating OLs. Recent reviews have
extensively discussed the cellular and molecular properties
of these ‘‘activated’’ OPCs and their developmental potential
in the context of demyelination/remyelination of adult brain
(Franklin and Gallo, 2014; Zuo and Nishiyama, 2013; Fancy
et al., 2011b). Our discussion will focus on the signaling
pathways shared between development and remyelination
and whether these represent true recapitulation of develop-
mental programs. Many developmental signals and associated
molecular pathways have been identified as either negative or
positive regulators of OL regeneration, and studies have inves-
tigated how those mechanisms interact with cellular changes
that occur in the pathological microenvironment of the adult
brain. This section will focus on OL regeneration and remyeli-
nation in animal models of demyelination, particularly models
of MS.
AnimalModels of Injury andPathology of theAdultWhite
Matter
Recent reviews have comprehensively and elegantly dis-
cussed all available animal models of MS and demyelinating
diseases (Franklin and Ffrench Constant, 2008; Ransohoff,
Table 1. Models of Adult Demyelination/Remyelination
Neuron
Review2012). These animal models (summarized in Table 1) have
been used extensively for revealing the endogenous remyeli-
nation potential of the central nervous system as a possible
therapeutic approach to functional recovery. For example,
the presence of OPCs in MS lesions is well established (Chang
et al., 2002; Wolswijk, 1998), so understanding their origin and
response to demyelinating insults is fundamentally important
to developing new cell-based strategies for remyelination.
OPC activation (i.e., changes in morphology, proliferation,
migration, and expression of specific genes) and recruitment
occur in all animal models of adult brain demyelination,
including experimental autoimmune encephalomyelitis (EAE)
and cuprizone- and lysolecithin (LPC)-induced demyelination(Aguirre et al., 2007; Cate et al., 2010; Messersmith et al.,
2000; Nait-Oumesmar et al., 1999; Picard-Riera et al., 2002).
These changes also occur in ‘‘activated’’ OPCs in MS tissue,
probably induced by signals present in lesions (Nait-Oumes-
mar et al., 2007).
Enhancers of Oligodendrocyte Development and
Regeneration
Several intrinsic and extrinsic regulators of OL development
have been identified as enhancers of regeneration (Figure 3),
opening up new opportunities to design molecularly targeted
approaches aimed at enhancing remyelination.
Growth Factors. During normal development, OPC prolifera-
tion and cell-cycle progression are positively regulated by twoNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 293
Figure 3. Positive and Negative Regulators
of Oligodendrocyte Development and
Regeneration
Schematic synopsis of the major developmental
phases of oligodendrocyte maturation—i.e., pro-
liferation, cell-cycle exit/differentiation and myeli-
nation—after demyelination of the adult brain.
Green arrows refer to enhancers of these pro-
cesses under pathological conditions, whereas red
arrows refer to inhibitory pathways. Preventing or
suppressing the inhibitory effects of specific path-
ways, as well as leveraging on enhancers promotes
oligodendrocyte maturation and myelination and
might define future cell-based therapeutic ap-
proaches to demyelinating diseases.
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and fibroblast growth factor 2 (FGF2)—that act either individually
or cooperatively through PDGFRa and FGFR1 to generate
mature OLs (Calver et al., 1998; Fortin et al., 2005; McKinnon
et al., 1990; Miller, 2002). Expression of the ligand PDGF-A is up-
regulated in reactive astrocytes of demyelinated lesions (Arm-
strong et al., 2002: Messersmith et al., 2000), and both FGF2
and FGFRs are upregulated in areas of acute or chronic cupri-
zone-induced demyelination (Messersmith et al., 2000). PDGF
and FGF2 control differential responses in the OL lineage after
demyelination (Murtie et al., 2005). Consistent with a role of
PDGF in proliferation, OPC amplification and subsequent repo-294 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.pulation of demyelinated lesions are
impaired in a heterozygote PDGFRa+/
or in a GFAP-driven PDGF-A null mouse
(Murtie et al., 2005). Conversely, FGF2
acts to inhibit remyelination through
FGFR1 (see below).
Stimulation of epidermal growth factor
(EGF) signaling is an example of success-
fully leveraging a developmental mecha-
nism to promote regeneration in the adult
brain. EGF exerts multiple effects on the
OL lineage, both OPCs and mature OLs
(Aguirre et al., 2007; Scafidi et al., 2014).
Selective EGFR overexpression in OL
lineage cells promotes OPC proliferation
and migration, enhancing the extent of
functional remyelination of the corpus cal-
losum after LPC-induced demyelination
(Aguirre et al., 2007). Consistent with
these findings, EGF infusion into the
lateral ventricle (Gonzalez-Perez et al.,
2009) or intranasal HB-EGF administra-
tion (Cantarella et al., 2008) promoted
OPC recruitment from SVZ to demyeli-
nated lesions. Furthermore, viral-medi-
ated EGFR overexpression in WM OPCs
increased proliferation and maintained
an undifferentiated phenotype (Ivkovic
et al., 2008). Other growth factors are
also involved in regulating OPC number
under physiological or pathological condi-tions: for example, analysis of null mouse strains demonstrated
that brain-derived neurotrophic factor (BDNF) is required to
regulate the number of OPCs during normal development and
during remyelination (Vondran et al., 2010; VonDran et al.,
2011). Together, these studies demonstrate that, similar to the
perinatal brain, specific GFs activate endogenous pools of
OPCs that can be redirected from proliferative areas to injury
sites to promote recovery in adults. The OPC response to demy-
elination and to cellular factors present in a lesion is integrated
by numerous cell-cycle regulatory proteins, including Cdk2
and p27Kip1, which regulate the number of OPCs recruited to a
lesion (Caillava et al., 2011; Crockett et al., 2005).
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demyelination have also identified factors that positively regulate
OPC differentiation and maturation of myelinating OLs under
normal physiological and pathological conditions. During normal
development, OL maturation is enhanced by ciliary neurotrophic
factor (CNTF) (Stankoff et al., 2002), which also exhibits a strong
promyelinating effect after demyelination (Albrecht et al., 2003).
Growth factor BDNF also promotes OPC differentiation and
myelin protein expression after cuprizone-induced demyelin-
ation, demonstrating that this factor modulates diverse phases
of the OL lineage (VonDran et al., 2011). Similarly, the neurotro-
phin NT-3 produced a broad range of developmental and
regenerative effects in OLs—promoting OPC proliferation and
supporting survival of mature OLs through TrkC receptors
and MAPK phosphorylation (Cohen et al., 1996). Notably, direct
NT-3 injection into the corpus callosum promoted oligodendro-
genesis and remyelination in a model of LPC-induced demyelin-
ation (Jean et al., 2003).
Insulin-like growth factor 1 (IGF-1) was identified early on as a
necessary factor for OL differentiation and myelination in vitro
and in vivo (Mozell and McMorris, 1991; Werther et al., 1998).
In vivo studies demonstrated that IGF-1 ablation causes reduced
brain size and hypomyelination (Beck et al., 1995; Ye et al.,
2002). The IGF type 1 receptor (IGF-1R) is continuously ex-
pressed throughout the entire OL lineage, and IGF-1 appears
to act at multiple developmental stages, promoting OPC prolifer-
ation, OL survival, and myelin synthesis (Barres et al., 1993; Ye
and D’Ercole, 1999; Zeger et al., 2007). Consistent with its mul-
tiple developmental roles, IGF-1 significantly attenuates the
damage induced by a demyelinating insult. In a transgenic
mouse strain expressing higher IGF-1 levels in the brain, the
cellular effects of cuprizone-induced demyelination on OL death
were significantly reduced, although significant demyelination
was seen. Furthermore, the remyelination rate was much higher
than in wild-type (WT) controls (Mason et al., 2000). Consistent
with these findings, IGF-1 decreased lesion severity and clinical
abnormalities in the EAE mouse model (Yao et al., 1995). These
results indicate that IGF-1 may improve recovery from a demye-
linating insult by selectively enhancing OPC differentiation and
supporting survival of the more mature OL population. However,
the experimental paradigm of enhanced IGF-1 expression might
be crucial, as increasing local IGF-1 mRNA levels by adenoviral
vector failed to promote remyelination (O’Leary et al., 2002).
How does IGF-1 promote OL survival and differentiation?
Analysis of signaling in OLs demonstrated IGF-1 to be a potent
activator of the PI3K/Akt and mTOR pathway (Min et al., 2012).
Exposure to IGF-1 maintains Akt signaling in differentiating
OPCs (Ness et al., 2002), consistent with the idea that IGF-1
signaling through PI3K/Akt and mTOR is functionally linked to
OPC differentiation into mature OLs. Recent research identified
mTOR as a critical signaling kinase in OL differentiation andmye-
lination and showed its effects occurring through the mTORC1
and mTORC2 signaling complexes (Tyler et al., 2009).
The preceding discussion of growth factors in demyelination
and remyelination points to the need for in vivo studies in various
animal models of pathology, each model designed to define
specific cellular and developmental effects of individual growth
factors on OL regeneration. The discussion also suggests thatsustained expression of various factors during distinct phases
of injury and recovery from a myelin insult might be used to co-
ordinate and integrate multiple cellular mechanisms that lead
to successful functional remyelination. Furthermore, analysis of
glial regeneration and repair should be extended to other cellular
factors that modulate glial development. For example, hepato-
cyte growth factor (HGF) has been identified as a positive
regulator of oligodendrocyte proliferation and migration and an
inhibitor of differentiation (Yan and Rivkees, 2002: Ohya et al.,
2007; Mela and Goldman, 2013). The role of HGF in remyelina-
tion has not been explored, but it might promote early phases
of OPC expansion and repopulation of demyelinated lesions.
Hormones. Several lines of evidence indicate that specific hor-
monal states regulate OL numbers, developmental myelination,
and myelin repair. Sexual dimorphism exists in rodent subcor-
tical WM, where females display a higher proportion of unmyelin-
ated axons (Kim and Juraska, 1997) and higher OL turnover
(Cerghet et al., 2006). MS occurs more frequently in females
and undergoes remission during pregnancy (Confavreux et al.,
1998), although the hormonal causes are poorly understood.
Interestingly, pregnant mice demonstrate an increase in newly
generated OLs and in the number of myelinated axons in corpus
callosum (Gregg et al., 2007), and pregnant mice show
enhanced ability to remyelinate after LPC-induced focal demye-
lination (Gregg et al., 2007). And prolactin has been identified as
a major regulator of OL plasticity and WM repair during preg-
nancy, inducing OPC proliferation and enhancing OL regenera-
tion in vivo (Gregg et al., 2007).
Thyroid hormone (triiodothyronine [T3]) is the best-studied
hormone for its effects on OL development. T3 regulates the
timing of OPC differentiation (Barres et al., 1994) and promotes
morphological maturation via a metabolic switch in OPCs that
supports myelin synthesis in mature OLs (Baas et al., 1997;
Younes-Rapozo et al., 2006). Specific cellular changes induced
by T3 have been extensively analyzed in purified cultured OPCs
or in reaggregating cultures (Baas et al., 1997; Jones et al., 2003;
Matthieu et al., 1992). In vivo, hypothyroidism causes delayed
and poor deposition of myelin during development (Ferreira
et al., 2004; Ibarrola and Rodrı´guez-Pen˜a, 1997), while hyperthy-
roidism accelerates myelination (Marta et al., 1998). Prolonged
neonatal hypothyroidism decreases the number of myelinated
axons in adult rats, although most of the myelinated axons
display normal thickness of the myelin sheath. Two animal
models of myelin pathology demonstrated the beneficial effects
of T3 on OL regeneration and remyelination. In the cuprizone
model, systemic T3 injection in rats significantly enhanced
remyelination by increasing the ratio of mature OLs to OPCs
(Franco et al., 2008). In the EAE model, T3 treatment yielded
myelin sheath and axonal protection and enhanced nerve con-
duction (Dell’Acqua et al., 2012). These cellular and physiological
studies support previous molecular analyses demonstrating
that T3 thyroid receptors can directly activate MBP and PLP
gene promoters in mature OLs (Farsetti et al., 1991; Bogazzi
et al., 1994).
The analysis of hormones in vivo reveals that both prolactin
and T3 promoteWMplasticity during development and in regen-
eration, implicating these hormones as potential therapeutic
agents for targeting axons and OLs in demyelinating diseases.Neuron 83, July 16, 2014 ª2014 Elsevier Inc. 295
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ences on OL development and regeneration, cytokines and
chemokines have been studied as factors predominantly upre-
gulated after demyelination. Tumor necrosis factor-a (TNFa) is
an inflammatory cytokine able to induce a broad range of cellular
responses, including cell proliferation and cell death, mediated
by the activation of two distinct receptors—TNFR1 (p55) and
TNFR2 (p75) (Dopp et al., 1997; Raine et al., 1998; Tche´linge´rian
et al., 1995). In the brain, TNFa is synthesized and released
by astrocytes and microglia (Liu et al., 1998). This cytokine was
shown to negatively regulate OPC number and differentiation,
as well as OL survival in developing cultured cells (Cammer
and Zhang, 1999). In keeping with these findings, studies in the
EAE model showed that genetic ablation or blockade of TNFa
signaling attenuated myelin pathology (Ho¨velmeyer et al.,
2005). However, analysis of TNFa and TNFR1 and TNFR2mutant
mice in a different model of demyelination also revealed a role
for this cytokine in OL regeneration and remyelination. Cupri-
zone-induced demyelination substantially increased TNFa and
TNFR2 in lesions, and genetic ablation of the cytokine caused
significant reduction in OL apoptosis, delayed demyelination,
and ultimately enhanced remyelination (Arnett et al., 2001).
TNFR2 was identified as the primary receptor mediating the in-
fluence of TNFa on remyelination, which was attributed to potent
effects on OPC proliferation and to generation of newOLs during
demyelination/remyelination (Arnett et al., 2001).
The mechanism of OL regeneration and its modulation
by TNFR2 appear complex. More recent analysis demon-
strated that TNFR2 also regulates expression of the chemokine
CXCL12, which acts on the CXCR4 receptor to modulate
remyelination. Interestingly, genetic ablation of TNFR2 causes
significant downregulation of CXCL12 expression in cuprizone-
induced lesions and decreases the number of CXCR4-express-
ing OPCs (Patel et al., 2012). Cellular analysis, combined with
rescue experiments, demonstrated that TNFR2 activation in as-
trocytes induces CXCL12 expression in demyelinated corpus
callosum, in turn promoting OPC proliferation and differentia-
tion. Consistent with this hypothesis, loss of CXCR4 signaling
decreased OPC maturation and prevented remyelination after
cuprizone-induced demyelination (Patel et al., 2010). As
CXCL12 also regulates normal OL development—in particular
OPC proliferation, migration, and differentiation (Dziembowska
et al., 2005; Patel et al., 2012)—the findings described above
indicate that reactivation of CXCL12 signaling has similar effects
on OL regeneration and remyelination.
Another cellular mechanism of action was attributed to the
proregenerative effects of yet another cytokine—Interleukin-1b
(IL-1b). This cytokine was shown to promote OL differentiation
after acute demyelination, as IL-1b/mice failed to properly re-
myelinate despite anOL depletion rate similar to that of wild-type
(WT) mice (Mason et al., 2001). The cytokine’s effects were indi-
rect and were attributed to delayed OPC differentiation due to
lack of IGF-1 produced by astrocytes and microglia (Mason
et al., 2001). These findings show cytokines acting at multiple
levels—both directly and indirectly—to regulate OL regeneration
and remyelination, and cellular interactions between OPCs, as-
trocytes, and microglia modulate all phases of remyelination.
These mechanisms are likely important for cell-based therapies,296 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.as recent studies of NSCs engrafted after demyelination re-
vealed a requirement for CXCL12 and CXCR4 signaling in NSC
migration and proliferation giving rise to OLs (Carbajal et al.,
2010).
Transcription Factors. Converting OPCs to a regenerative
phenotype is thought to involve enhanced expression and activ-
ity of several transcription factors playing important roles in OL
development. A number of studies indicate that multiple tran-
scription factor networks probably regulate OPCs’ response to
demyelination, modulating OL regeneration. During develop-
ment, Olig1, Olig2, and Nkx2.2 are crucial in OL specification
and maturation (Lu et al., 2002; Soula et al., 2001), and expres-
sion of transcription factors that regulate OL fates—including
Olig2 and Nkx2.2—is enhanced in adult OPCs after demyelin-
ation (Fancy et al., 2004). This upregulation is generally observed
during acute phases of demyelination and during early
remyelination, indicating that OPC transition to a regenerative
phenotype probably involves recapitulation of developmental
programs. Although some transcription factors may play roles
in both development and repair of glia, others—like Olig1—
appear to be primarily involved in repair. Given that remyelination
is less efficient in Olig1/ mice, Olig1 is regarded as crucial in
myelin repair in the adult brain, although this factor is redundant
in OL development (Arnett et al., 2004). Indeed, Olig1 displays
nuclear localization in early remyelinating lesions in animal
models of demyelination and inMS tissue, but ismostly cytosolic
in normal WM (Ligon et al., 2006). A similar expression pattern is
observed for transcription factor Myt1, which appears to modu-
late OPC proliferation and contribute to the timing of differentia-
tion (Nielsen et al., 2004; Vana et al., 2007).
Two other transcription factors—Ascl1/Mash1 and Sox17—
belong to distinct families and play differing roles in OL develop-
ment and regeneration. The proneural gene Ascl1/Mash1 was
newly identified as a regulator of embryonic and postnatal oligo-
dendrogenesis (Parras et al., 2004, 2007). In the embryonic CNS,
Ascl1 is expressed in ventral forebrain and cooperates with Olig2
to specify OPCs (Parras et al., 2007). In the postnatal SVZ, Ascl1
is expressed in progenitors of both OL and neuronal lineages
(Parras et al., 2004; Nakatani et al., 2013) and positively regulates
OPC specification as well as the balance between proliferation
and differentiation. In the animal model of lysolecithin-induced
focal demyelination, Ascl1 activity is upregulated during OL
regeneration, and Ascl1 is required for proper remyelination
from OPCs (Nakatani et al., 2013). Importantly, Ascl1 expression
is also enhanced in MS chronic active lesions (Nakatani et al.,
2013).
Another group of transcription factors are induced by injury,
inhibit OPC proliferation, and increase cell differentiation, but
have complex effects on various neural cell lineages. In the OL
lineage, expression of Sox17 RNA and protein peaks at P15
and precedes myelin gene expression (Sohn et al., 2006). Unlike
Ascl1, Sox17 does not appear to be involved in OPC specifica-
tion but rather in cell-cycle exit and initiation of differentiation
(Sohn et al., 2006). Developmental studies in cultured cells and
transgenic mice in vivo demonstrated that Sox17 promotes
OPC differentiation by inhibiting the Wnt/b-catenin pathway
(Chew et al., 2011; Ming et al., 2013). Extensive analysis of
Sox17 expression and regulation in animal models of
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expression is highest in newly generated OLs, suggesting a
role for this transcription factor in OL regeneration (Moll et al.,
2013). In MS tissue, Sox17 is highly expressed in chronic active
lesions (Moll et al., 2013). Finally, selective overexpression of
Sox17 in the OL lineage strongly attenuated the effects of
LPC-induced demyelination by promoting OPC differentiation
and OL survival (Ming et al., 2013), indicating that sustained acti-
vation of Sox17 promotes OL regeneration and myelin repair.
Retinoic acid receptor signaling strongly induces neuronal dif-
ferentiation during embryonic development and in adult NSCs
(Bain et al., 1996; Goncalves et al., 2005). In addition, retinoid
X receptor gamma (RXR-gamma) (Huang et al., 2011) positively
regulates OL differentiation during myelination and remyelina-
tion. Nuclear translocation of RXR-gamma was noted during
OPC differentiation and OL regeneration and, importantly, pre-
dominantly nuclear RXR-gamma was detected in OPCs in MS
tissue within active lesions, periplaque WM, and remyelinated
plaques. Thus, its presence in the nucleus was consistent with
cellular activity and repair capacity in MS. The finding that sys-
temic administration of 9-cis retinoic acid after demyelination
promoted axonal remyelination (Huang et al., 2011) demon-
strates that activating this pathway is a potentially effective treat-
ment for demyelinating lesions.
The findings described above indicate that several intrinsic
regulators of OL development are important in regeneration
and myelin repair. While direct targeting of transcription factors
may represent a challenge in regenerative therapies, elucidating
the signaling pathways regulated by these factors will open new
avenues for molecularly targeted approaches to myelin repair.
Furthermore, identifying the transcription factors that promote
an OL phenotype under physiological and pathological condi-
tions will enhance the efficiency of OL generation in cell-based
therapies involving NSCs or induced pluripotent stem cells
(iPSCs).
Other Signaling Pathways. The morphogen Sonic Hedgehog
(Shh) is another example of reactivation of a developmental
signal during OL regeneration (Ferent et al., 2013). Shh is
required for OPC specification during embryonic development
(Orentas et al., 1999; Spassky et al., 2001) and regulates OL pro-
duction in adult cortex and corpus callosum (Yung et al., 2002).
In LPC-induced focal demyelination, Shh transcripts and protein
were upregulated in OL lineage cells within the lesion in a time-
dependent fashion; furthermore, increased transcription of Shh
target genes showed significant reactivation of the Shh pathway.
Gain- and loss-of-function analyses demonstrated that Shh
signaling plays a positive role in OL regeneration and myelin
repair, enhancing OPC proliferation and differentiation as well
as OL survival. Yet, activation of Shh signaling decreased astro-
gliosis and macrophage infiltration (Ferent et al., 2013), indi-
cating that some of these beneficial effects may be indirect.
Reactivation of signaling pathways that stimulate OPC migra-
tion also occurs after demyelination. Netrin-1 positively regulates
OPCmigration in the postnatal optic nerve (Spassky et al., 2002),
and a recent study demonstrated involvement of Netrin-1 in
promoting migration of OPCs out of the adult SVZ after LPC-
induced demyelination (Cayre et al., 2013). Netrin-1 was strongly
upregulated in the SVZ after demyelination and was identified asthe signal involved in local angiogenesis and progenitor cell
migration, likely by activation of deleted in colorectal cancer
(DCC) and neogenin receptors (Cayre et al., 2013). Demyelin-
ation induced vascular remodeling in the SVZ, and VEGF-
mediated progenitor cell recruitment occurred with specific
association between reactive blood vessels and OPCs (Cayre
et al., 2013).
Metalloproteinase inhibitors may also play positive roles in OL
regeneration in response to injury. Recent analysis demon-
strated that myelin injury upregulates tissue inhibitor of metallo-
proteinase (TIMP-1) in reactive astrocytes, regulating secretion
of matrix metalloproteinases from these cells (Nyga˚rdas and
Hinkkanen, 2002). Analysis in TIMP-1 null mice showed that
oligodendrogenesis and compact myelin formation are signifi-
cantly impaired, at least partly due to a reduced number of
OPCs (Moore et al., 2011). In EAE, TIMP-1 expression is associ-
ated with astrocytes in demyelinated lesions, and remyelination
is impaired in TIMP-1 null mice (Crocker et al., 2006). In clinical
studies, robust TIMP-1 expression was found in acute demye-
linating diseases that display some degree of remyelination
(Ichiyama et al., 2006), while cerebrospinal TIMP-1 levels are
not modified in MS (Avolio et al.,, 2003).
Inhibitors of OL Development and Regeneration
Mechanisms underlying the failure of remyelination in WM
lesions include depletion of the endogenous OPC pool, limited
migration of endogenous OPCs in a pathological environment,
loss of axonal signals that support OPC-derived remyelination,
and presence of inhibitors (likely produced by both astrocytes
and infiltrating microglia) preventing their complete differentia-
tion (Chong and Chan, 2010; Mason et al., 2004; Miron et al.,
2013). Many of these inhibitors also negatively regulate normal
OPC development (Figure 3).
A fundamental phase in OL development consists of OPC
proliferation and the generation of sufficient OLs. Proteins that
regulate cell-cycle progression and cell-cycle exit in OPCs—
i.e., ultimately, the number of OPCs—have been intensely
analyzed for their roles in development and repair. During normal
development, type 2 cyclin-dependent kinase (Cdk2) is neces-
sary for OPC proliferation but does not affect differentiation
(Belachew et al., 2002). However, after demyelination, loss of
Cdk2 accelerates CNS remyelination by altering OPC cycle
exit and enhancing differentiation, indicating Cdk2 to be an
inhibitor of OL maturation in pathology (Caillava et al., 2011).
Recruitment of progenitors to a demyelinated lesion in spinal
cord is negatively regulated by Cdk2 inhibitor p27Kip1, as more
OPCs were found in the lesion of p27Kip1 null mice than in WT
controls, and these cells differentiated into mature OLs (Crockett
et al., 2005). The other Cdk inhibitor, p57Kip2, appears to have a
different role, as it prevents OL differentiation and remyelination
in the EAEmodel (Kremer et al., 2009). This is consistent with the
finding that suppressing p57Kip2 expression promotes oligoden-
drogenesis from NSCs (Jadasz et al., 2012). Together, these
findings indicate that failure to remyelinate may be due, at
least partly, to cell-cycle regulators that inhibit OL maturation
from OPCs.
Studies of cellular factors identified inhibitors that should,
ideally, be eliminated from a demyelinated lesion to promote
regeneration of mature OLs. These inhibitors—BMP, FGF2,Neuron 83, July 16, 2014 ª2014 Elsevier Inc. 297
Figure 4. Oligodendrocyte Regeneration
through Lineage Plasticity of
GAD-Expressing Neuroblasts
Demyelination of the adult white matter (corpus
callosum) causes fate plasticity in GAD-expressing
(GAD+) neuroblasts of the subventricular zone
(SVZ). Under normal physiological conditions,
Olig2 expression is repressed by BMP signaling
in GAD+ neuroblasts. Demyelination causes upre-
gulation in the levels of the BMP antagonist chordin
in the SVZ, which prevents BMP signaling and re-
sults in induction of Olig2 expression in GAD+ cells.
These cells migrate out of the SVZ into the corpus
callosum, where they generate mature, myelinating
oligodendrocytes (see Jablonska et al., 2010).
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drogenesis during normal development. During development,
BMP signaling suppresses oligodendrogenesis, promoting neu-
rogenesis (Colak et al., 2008) and astrogliogenesis (Gomes et al.,
2003; Samanta et al., 2007; See et al., 2007; See and Grinspan,
2009). BMPs negatively control OPC specification and lineage
commitment, as well as OPC maturation into myelinating OLs
(See et al., 2007). These effects likely involve induction of inhib-
itor of differentiation (Id) expression and inhibition of Olig activity
(Samanta and Kessler, 2004; Chen and Panchision, 2007). BMP
expression is enhanced in several animal models of CNS injury
(Ara et al., 2008; Chen et al., 2005; Hampton et al., 2007; Mat-
suura et al., 2008) and—consistent with the complex develop-
mental functions of BMPs—this can exert opposite effects on
neural cell regeneration after injury. In animal models of demye-
lination, the expression of BMP-4, BMP-6, and BMP-7 is upregu-
lated (Ara et al., 2008; Fuller et al., 2007; Sabo et al., 2011) and
BMPs likely released by neurons and astrocytes inhibit remyeli-
nation and impair recovery (See and Grinspan, 2009). Infusing
the BMP antagonist Noggin into demyelinated lesions increased
the density of mature OLs during remyelination of the CC (Sabo
et al., 2011). The BMPantagonist chordin was identified as a SVZ
signal that promotes oligodendrogenesis fromGAD65- and Dcx-
expressing neuroblasts of the adult SVZ (Figure 4), indicating
that niche-dependent mechanisms regulate lineage plasticity
of progenitors in the adult brain (Jablonska et al., 2010). In
contrast to the role of FGF2 (or FGFR1) in normal development,
their genetic ablation under pathological conditions dramatically
enhanced OL regeneration by promoting OPC differentiation
(Armstrong et al., 2002; Zhou et al., 2012), indicating that this
growth factor actually inhibits OPCmaturation in a demyelinated
lesion. Thus, manipulation of BMP and FGF in a demyelinated
lesion environment illustrates how the extent of remyelination298 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.from endogenous OPCs can be enhanced
by differentially modulating activity of spe-
cific developmental signals.
Notch signaling was also identified as a
developmentally regulated inhibitor of
OPC maturation, as downregulation of
this pathway is required for OL differentia-
tion andmyelination (Hu et al., 2003;Wang
et al., 1998). Suppressors of Notch
signaling enhance OPC maturation duringnormal development (Aguirre et al., 2010; Hu et al., 2003; Wang
et al., 1998). Interestingly, Notch signaling in adult brain is reacti-
vated after demyelination of the CC (Hammond et al., 2014;
Zhang et al., 2009), and Jagged 1 upregulation found in MS
chronic lesions (John et al., 2002) suggests that activated Notch
contributes to preventing endogenous OPC maturation and re-
myelination. The question is: which endogenous signals activate
Notch after demyelination, and how is Notch activated in OPCs?
Our recent study using a transgenic Notch-reporter mouse
showed that the peptide Endothelin-1 (ET-1) is a major regulator
ofNotchafter focal LPC-induceddemyelination (Hammondet al.,
2014). ET-1 is upregulated in mouse and MS reactive astrocytes
and induces Jagged 1 expression in these cells, which in turn ac-
tivates Notch and delays OL maturation after demyelination.
These findings suggest that ET-1 is oneofmany signals that regu-
late Notch in a demyelinated lesion and in MS and that various
cellular factors in pathological WM might converge on the inhib-
itory Notch ‘‘hub’’ in developing and adult brain.
OL differentiation and activation of the myelination program
are both essential in timely myelination. Like Notch, LINGO-1—
another inhibitor of OL differentiation and myelination—is a
modulator of cell-cell interactions that precisely regulate the
timing of myelination (Mi et al., 2005). LINGO-1 is a transmem-
brane protein selectively expressed in the CNS, specifically in
axons and OPCs (Mi et al., 2005). LINGO-1 is a component of
the Nogo receptor complex and its expression is developmen-
tally regulated (Mi et al., 2004). Studies in cultured cells and
knockout mice demonstrated that downregulation of LINGO-1
promotesOL differentiation andmyelination during development
(Mi et al., 2005). Importantly, LINGO-1 is upregulated in a variety
of animal models of CNS pathology, including the EAE model of
MS in which functional blockage of LINGO-1 enhances OL
regeneration and remyelination and promotes functional
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rons directly regulate OPC development, myelination, and re-
myelination: Semaphorin 3A and 3F (Sema 3A and 3F) exert
opposite effects—chemorepulsive and chemoattractive,
respectively—on OPC migration (Okada et al., 2007; Syed
et al., 2011; Xiang et al., 2012). Both Sema 3A and 3F are upre-
gulated in demyelinated lesions and in MS but appear to play
different functional roles in OPC-derived remyelination. Loss-
and gain-of-function analysis demonstrated that Sema 3A is
needed for OPC recruitment and repopulation of the demyeli-
nated lesion, whereas Sema 3F promotes both OPC recruitment
and remyelination (Syed et al., 2011). Together, these findings
indicate that population of the adult WM, as well as OL differen-
tiation during myelination and remyelination, are finely regulated
by multiple interactions between OPCs and neurons.
Genome-wide screening has been extensively used to identify
novel regulators of OPC development, and a screen performed
in remyelinating rodent lesions found 50 transcription factors
regulated during regeneration (Fancy et al., 2009). These
included the Wnt pathway mediator Tcf4, indicating that activa-
tion of this pathway may be involved in delaying myelin recovery.
Subsequent gain- and loss-of-function analysis demonstrated
that the canonical Wnt pathway negatively regulates OL differen-
tiation during developmental myelination and remyelination
(Fancy et al., 2009). The effects of Wnt are mediated by BMPs
(Feigenson et al., 2011). But how do OPCs and OLs eventually
overcome this pathway’s inhibitory effects when remyelination
does occur? Recent analysis identified transcription factor
Sox17 as a suppressor of Wnt/b-catenin, consistent with its
role as a positive regulator of OL maturation and regeneration
during normal development (Chew et al., 2011). Sox17 was first
identified as a transcription factor that promotes OPC cycle exit
and induces differentiation. After demyelination, Sox17 levels are
highest in newly generatedOLs and activeMS lesions (Moll et al.,
2013) and its selective overexpression in the OL lineage pro-
motes remyelination (Ming et al., 2013). These findings, along
with enhanced remyelination induced by Axin 2 targeting (Fancy
et al., 2011b), indicate the Wnt/b-catenin pathway as a strong
therapeutic target in adult myelin regeneration.
Another type of inhibitor of OLmaturation is directly linked to a
specific role in OL survival. Death receptor 6 (DR6), a member of
the TNF receptor (TNFR) superfamily, is expressed at high levels
in immature OLs but downregulated inmyelinating cells (Mi et al.,
2011). Enhanced DR6 expression causes caspase 3 (casp3)
activation and cell death, whereas attenuation of DR6 function
promotes OL maturation, myelination, and casp3 downregula-
tion (Mi et al., 2011). In two different animal models of demyelin-
ation, genetic ablation of DR6 enhanced remyelination, and
treatment with a DR6 antagonist antibody had the same effect
(Mi et al., 2011). These findings reveal not only a crucial role for
DR6 in OL development, regeneration, and in remyelination,
but also a cellular mechanism that could be targeted in MS to
promote remyelination and inhibit the autoimmune component
of the disease.
Epigenetic Regulation
Epigenetic mechanisms also regulate OL regeneration and re-
myelination in adult WM. After demyelination of young brains,
HDACs are efficiently recruited to promoter regions of differenti-ation inhibitors to promote remyelination; however, this process
is impaired in old animals, whose accumulated transcriptional
inhibitors prevent myelin gene expression and efficient remyeli-
nation (Shen et al., 2008). Treating young animals with HDAC-
inhibitor valproic acid reproduces the defect observed in adults
(Shen et al., 2008), indicating that the age-dependent decrease
in remyelination efficiency is—at least in part—due to epigenetic
modulation of OL differentiation potential. Importantly, the OL-
specific transcription factor TCF7L2/TCF4—a bipartite coeffec-
tor of b-catenin—was also shown to mediate cross talk between
HDAC1/2 and the Wnt signaling pathway to regulate OL differ-
entiation (Ye et al., 2009). Similar to mice lacking HADC1 and
2, TCF7L2 null mutants displayed impaired remyelination (Ye
et al., 2009). Together, these results indicate that HDACs repre-
sent important molecular targets for promoting remyelination
under pathological conditions.
Conclusions and Future Directions
The rapid and significant progress in understanding astrocyte
and OL development and pathology continues to raise important
questions about the role of these cells in human neurological dis-
orders and brain injury. These glial cells clearly play crucial roles
in virtually all brain pathologies and defining their role in brain dis-
ease will also provide information about the function of astro-
cytes andOLs in normal brain development. Continuing to define
the cellular, molecular, and physiological properties of glial pop-
ulations is essential to gain a true understanding of relationships
between neural development and regeneration.
A first critical issue in future studies on the roles of astrocyte
andOL progenitors in disorders of the developing and adult brain
is the lack of specificmolecular tools that enable the heterogene-
ity of these cell populations tobe resolved.Onceglial populations
of different brain regions are identified and isolated, advanced
molecular and genetic techniques can be applied to discover
crucial genes that regulate their functional properties under
normal and pathological conditions. Lineage reporters combined
with gene expression profiling, and chromatin immunoprecipita-
tion (ChIP)-on-ChIP, chromatin immunoprecipitation sequencing
(ChIP-seq), and RNA sequencing (RNA-seq) assays can be also
used to isolate genes preferentially expressed in glial cell sub-
types and todefine sets of developmentally regulated glial genes.
Genome-wide screening in specific identified glial progenitor
cell subpopulations will help identify spatiotemporally restricted
expression patterns of transcription factors, as well as other mo-
lecular regulators of glial development (Fu et al., 2009) and regen-
eration (Fancy et al., 2009). Such studies are essential entry
points for the isolation and subsequent characterization of these
factors and regulators in the developing and injured CNS. These
approacheswill also help todeterminehowgenetic defects affect
glial lineages and the impact of altered glial development on
normal brain function. Protein products of genes involved in neu-
rodevelopmental disorders (Pacey and Doering, 2007) or in adult
neurological diseases (Rempe and Nedergaard, 2010) may be
expressed in glial progenitor cells and impair specific signaling
pathways. Future research will reveal how specific glial defects
contribute to these and other brain disorders and to brain injury.
A second critical issue for future research is glial progenitor
fate plasticity, particularly the identification in vivo ofNeuron 83, July 16, 2014 ª2014 Elsevier Inc. 299
Neuron
Reviewmicroenvironmental factors that favor or restrict fate plasticity in
glia within the intact CNS. Understanding this phenomenon and
its underlying mechanisms is important for manipulating not only
the fate of endogenous glial progenitor cells but also the fate of
progenitors grafted into the pathological brain. Recent studies
have identified new roles for the vasculature and endothelial cells’
response to injury in modulating glial progenitor cell proliferation,
migration, and differentiation (Cayre et al., 2013; Goldman and
Chen, 2011). Therefore, signaling pathways that regulate glial pro-
genitor-vasculature interactions might also represent attractive
targets for enhancing glial regeneration under pathological condi-
tions.
Another topic for future study is the progressive changes in
cellular andmolecular properties experienced by glial progenitor
cells during CNS development and aging. For example, the re-
myelinating potential of OPCs decreases from early postnatal
development to adulthood (Sim et al., 2002) and astrocytes
outside the classic neurogenic areas undergo progressive line-
age restriction and lose their neurogenic potential (Berninger,
2010; Bi et al., 2011; Laywell et al., 2000). It is crucial to continue
characterizing the molecular and cellular mechanisms that regu-
late timely generation and lineage progression of different glial
types in the developing CNS, to define: (1) the determinants of
developmental time windows for neurogenesis, gliogenesis,
and proper functional maturation of the brain, and (2) the poten-
tial for extending these time windows for regenerative purposes.
Finally, advances in iPS and ES cell technology hold great
promise for cell-replacement therapies across a spectrum of
tissues and associated pathologies. Several groups have estab-
lished protocols to derive astrocytes and OLs, providing a
foundation for translational applications. The likely application
of this technology in glial repair is in WMI and OL replacement,
as myelin sheath restoration is the clear focus of these therapeu-
tic interventions. For astrocytes, the goal is less clear, as their
complex roles in injury (protective versus inhibitory), injury condi-
tions, and cellular heterogeneity make modeling of these condi-
tions very difficult. Future in vivo studies aimed at understanding
how different forms of injury differentially harness the reactive
astrocyte response are essential for developing iPS or ES ap-
proaches to generating protective and regenerative astrocytes
for cell-based therapies.
Resolving the issues in brain pathology discussed above will
be critical to further elucidate relationships between glial cell
populations in rodent models and their human counterparts,
providing a better perspective on how to harness knowledge
of glial development for therapeutic purposes. In addition, new
techniques applied in parallel to human and animal brains—in
particular noninvasive neuroimaging (e.g., fMRI, DTI, in vivo
spectroscopy), as well as molecular analysis of postmortem
tissue or surgical specimens—will determine how findings in
animal models of disease relate to human conditions. The gener-
ation of more sophisticated animal models that incorporate
the genetic heterogeneity seen in humans (Niu et al., 2014) will
also promote better translation of animal research to clinical con-
ditions. Thus, studies of glial cells and their responses to injury
and pathology present a unique opportunity to interface studies
in animal models of disease with neurodevelopmental disorders
and diseases of the adult human brain.300 Neuron 83, July 16, 2014 ª2014 Elsevier Inc.ACKNOWLEDGMENTS
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